RESEARCH + DEVELOPMENT

KPS develops, validates molecular diagnostic tests and provides molecular pathology services to detect predictive biomarkers in tumor samples for personalized targeted therapies

Why KPS?

  • In KPS you find special know-how in molecular pathology in combination with state-of-the art R&D infrastructure and internationally trained management. 

  • KPS is a fully independent private company, therefore intellectual property and confidentiality is most protected. 

  • In Hungary you find EU conform regulatory environment, western-style working moral at low cost, this is why Hungary is already a preferred clinical and translational research site of international pharma companies. In addition, state and EU provided applied research grants are also available.

Download our brochure (330kB, PDF)

100% at the KRAS European External Quality Assessment Schemes 2010

As the only Hungarian diagnostic service provider KPS Molecular Diagnostics scored 100% at KRAS European External Quality Assessment Schemes 2010 organized by the European Society of Pathologists. Samples for the KRAS European external quality assessment scheme 2010 were dispatched in July 2010. Each participant received 3 unstained sections, paraffin-embedded material from 10 invasive colorectal carcinomas to be analysed for the presence of KRAS mutations. From 27 participating laboratories, 21 reported all 10 genotypes correctly. KPS scored 100% which is above the average European genotyping score 94%. Results of the KRAS European external quality assessment scheme 2010 were evaluated and discussed in the QAu ESP working group on 19/10/2010. This EQA Report is authorized by Prof Dr J Van Krieken and Prof Dr E Dequeker.     More»


Further news

KPS is on the genomic map of the world

  KPS Molecular Diagnostics has been chosen as a key genomic infrastructure provider in the Central-European Region. The University of Birmingham published the list "Next Generation Genomics: World Map of High-throughput More»

Our genome sequencing lab is a part of the national r&d infrastructure network

Our genome sequencing laboratory and our Roche FLX Genome Sequencer FLX System was certified as a strategic research infrastructure by the National R&D Infrastructure Survey in this month. The Hungarian National R&D Infrastructure More»

Our publication has been released in Nature Reviews Drug Discovery

In July, Nature Reviews Drug Discovery will publish our CEO's paper about the chances of development of novel drug compounds and targeted therapy in the future. In the 1990s, the breast cancer drug trastuzumab (Herceptin; Genentech/Roche) More»

The benefit of science TODAY

The emergence of molecular-targeted medicine at the turn of the 21st century brought a breakthrough in the personalized treatment of tumors and inflammations, comparable only to the discovery of penicillin. At the turn of the nineteenth More»